ncRNA basic information
ncRNA ID:
MI0016748
ncRNA Database:
miRBase
ncRNA Name:
miR-1268b
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
RT-qPCR
ncRNA Target Gene:
ERBB2
ncRNA Pathway:
PI3K-AKT pathway
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00997 (APRD00185, DB05331, DB05847)
Drug Name:
Adriamycin
Drug Method:
Selected from miRNA microarray and confirmed by real-time quantitative PCR (RT-qPCR), miR-1268b was found to be significantly upregulated in drug sensitive and ERBB2 negative tissues, as well as in breast cancer patients with low clinical stage. And miR-1268b had a higher expression in chemosensitive breast cancer cell lines, compared with the chemoresistant cell line. Moreover, the results revealed that miR-1268b induced breast cancer cell apoptosis and increased cell chemosensitivity. ERBB2 was demonstrated to be the target gene of miR-1268b by dual-luciferase reporter assays, western blot, and immunocytochemistry. Furthermore, PI3KCA, AKT, BCL2 in the ERBB2-PI3K-AKT signaling pathway were found to be downstream effectors of miR-1268b. In conclusion, miR-1268b increased chemosensitivity, at least in part, via modulation of PI3K-AKT pathway by targeting ERBB2.
Drug Response:
sensitive
Cancer basic information
Cancer:
breast cancer
Tissue/Cell:
cell line (MDA-MB-231, MDA-MB-468, MDA-MB-453 SKBR3, MCF-7,MCF-7/ADM)
Other information
Title:
MiR-1268b confers chemosensitivity in breast cancer by targeting ERBB2-mediated PI3K-AKT pathway.
Journal:
Oncotarget
Published:
2017
PubMed ID:
29163776